65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

J.K. Schwarze, C. Bertels, G. Awada, J. Tijtgat, S. Tuyaerts, L. Cras, F. Vaeyens, A-M. Vanbinst, H. Everaert, A. Michotte, B. Caljon, C. Olsen, T. Janssen, S. Van Dooren, R. Forsyth, J. Duerinck, B. Neyns

Research output: Contribution to journal › Meeting abstract (Journal)

Fingerprint

Dive into the research topics of '65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma'. Together they form a unique fingerprint.

Medicine & Life Sciences